The invention relates to a monolithic peroral dosage form which allows a modified release, preferably an extended and delayed release, of an active ingredient combination of active ingredients with solubility properties that strongly deviate from one another. The dosage form comprises at least one emulsifier with a polyalkylene oxide structural motif and at least one controlled -release agent. Using the dosage forms according to the invention , even active ingredients which have a limited storage stability and other unfavorable active ingredient properties that additionally hinder processing can be featured in an optimal manner. The invention also relates to a method for producing the dosage form and to the use thereof.
